RIO-LIPIDS研究PPT课件.ppt

《RIO-LIPIDS研究PPT课件.ppt》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、RimonabantinObesityPresentedatAmericanCollegeofCardiologyScientificSessions2004PresentedbyDr.Jean-PierreDespresRIOLIPIDSTrialRimonabantAselectivecannabinoidtype1receptorantagonist5mgn=345Endpoints(1year):Weightloss5%ofbodyweightand10%ofbodyweightChangeinlipidpr

2、ofileRIOLIPIDSTrialPresentedatACCScientificSessions20041,036patientswithabdominalobesityandabnormallipidprofilesRandomized,double-blind,multicenterPlacebon=342RimonabantAselectivecannabinoidtype1receptorantagonist20mgn=346Treatmentfor1YearRIOLIPIDSTrialWeightLoss

3、5%p<0.001forhigh-dosevsplaceboPresentedatACCScientificSessions2004WeightLoss10%p<0.001forhigh-dosevsplaceboRIOLIPIDSTrialRelativeReductioninCRPp=0.007forrimonabant20mgvsplaceboC-reactiveproteinreductiongreaterinrimonabant20mgarmcomparedwithplacebo(from3.7to2.7m

4、g/lwithrimonabant20mgvs.3.6to3.2mg/lwithplacebo,p=0.007)HDLincreased23%andtriglyceridesdecreased15%inrimonabant20mg,butnosignificantdifferenceinLDLlevelsPresentedatACCScientificSessions2004RIOLIPIDSTrialAmongpatientswithabdominalobesityandabnormallipidprofiles,us

5、eoftheselectivecannabinoidtype1receptorantagonistrimonabantina5mgor20mgdosewasassociatedwithgreaterweightreductionafter1yearoftreatmentcomparedwithplaceboAdditionalbenefitswereobservedinHDLandtriglyceridelevelswithrimonabantObesityisagrowingepidemic,whichhasbeens

6、howntocontributetoavarietyofco-morbidities,includingincreasedcoronaryheartdisease,diabetes,andhyperlipidemiaFewpharmacologicagentshavebeenidentifiedasbothsafeandeffectiveinreducingweight,pointingtothepotentialimportanceofthepresentstudyFurtherevaluationiswarrante

7、d